Thromboembolic disease in females and males aged 10 to 39 years in Germany
Abstract
Abstract.Background: We analysed differences in hospitalization rates for venous diseases such as pulmonary embolism (PE), deep vein thrombosis (DVT), sinus vein thrombosis (SVT), portal vein thrombosis (PVT), and Budd-Chiari syndrome (BCS) as well as for arterial diseases such as myocardial infarction (MI) and embolic stroke (ES) in females and males aged 10 to 39 years. Patients and methods: Detailed lists of hospitalizations with the principal and additional diagnoses for PE (ICD-code I26.0 + I26.9), DVT (I80.0–I80.9), SVT (I67.6), PVT (I81), BCS (I82.0), MI (I21.0–I21.9), and ES (I63.1 + I63.4) in males and females aged 10 to 39 years in the years 2006 to 2015 were provided by the Federal Statistical Office in Germany. Results: Considering the 10-year period there were more female than male cases hospitalized with the principal diagnoses for PE, DVT, SVT, and BCS. Looking at the principal diagnosis of the year 2015, one can see a steep increase in numbers of hospitalization for PE, DVT, and SVT in females ranging from the ages 12 to 13 and 14 to 15 years compared to males. The curves of PE and DVT meet again in the age group between 32 and 33 years, but not for SVT. The greatest differences are seen at the end of the second and at the beginning of the third decade of life. In contrast, MI was more frequent in young males beginning at the age of 18 to 19 years. The number of female and male cases with ES and PVT were almost similar in the different age groups. Conclusions: The presented data show higher hospitalization rates for females in the age group 10 to 39 years for different venous thrombosis but not for MI and ES.
Literature
Analysis of risk factors of stroke and venous thromboembolism in females with oral contraceptives use. Clin Appl Thromb Hemost. 2018;24(5):797–802.
. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011;183(18):E1319–25.
. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011;342:d2151.
. Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand. 2012;91(7):769–78.
. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States. Am J Obstet Gynecol. 1999;180(1 Pt 1): 241–9.
. Pillenreport – Ein Statusbericht zu oralen Kontrazeptiva. Universität Bremen, SOCIUM, 2015.
. Disproportional increase of pulmonary embolism in young females in Germany: trends from 2005 to 2014. J Thromb Thrombolysis. 2017;43(3): 417–22.
. Pulmonary embolism in young people. Trends in Germany from 2005 to 2011. Hamostaseologie. 2014;34(1):88–92.
. Nationwide rates of conversion from laparoscopic or vaginal hysterectomy to open abdominal hysterectomy in Germany. Eur J Epidemiol. 2011;26(2):125–33.
. Effect of mammography screening on surgical treatment for breast cancer: a nationwide analysis of hospitalization rates in Germany 2005–2009. Eur J Epidemiol. 2013;28(8):689–96.
. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017; 118:79–83.
Oral contraceptives and blood diseases are the most common causes of Budd-Chiari syndrome. Lakartidningen. 1989; 86:4002–8.
. Diagnosis and treatment of cerebral venous and sinus thrombosis. Curr Neurol Neurosci Rep. 2014;14(1):417.
. Two women with cerebral venous thrombosis: oral contraceptives? West Indian Med J. 2013;62(3):260–3.
. Acquired and congenital risk factors associated with cerebral venous sinus thrombosis. Thromb Res. 2010;126(2):81–7.
. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch. Contraception. 2006;74(4):290–2.
. Budd-Chiari syndrome induced by hormonal oral contraception in the patient with congenital thrombophilia-factor V Leiden mutation – a case report. Ginekol Pol. 2008;79(10):702–5.
European Stroke Organization. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology. Eur J Neurol. 2017;24(10):1203–13.
. Cerebral venous sinus thrombosis: update on diagnosis and management. Curr Cardiol Rep. 2014;16(9):523.
. Portal vein thrombosis associated with prolonged ingestion of oral contraceptive steroids. J Gastroenterol Hepatol. 1993;8:390–3.
. Massive mesenteric and portal venous thrombosis secondary to hormone replacement therapy. Scott Med J. 2013;58(4):e8–10.
. Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. J Clin Gastroenterol. 1999;29(1):90–5.
Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;216(5):489.e1–489.e7.
. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;8:CD011054.
. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception. 2016;94(6): 590–604.
Prevalence, Clinical Features, and Prognosis of Acute Myocardial Infarction Attributable to Coronary Artery Embolism. Circulation. 2015;132(4):241–50.
Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016;353:i2002.
. Acute myocardial infarction among Icelanders forty years old and younger 2005–2009. Comparison with a study carried out 1980–1984. Laeknabladid. 2017;103(1):11–5.
. Young Women With Acute Myocardial Infarction: Current Perspectives. Circ Cardiovasc Qual Outcomes. 2017;10(2): pii:e003480.
